<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820585</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-210</org_study_id>
    <nct_id>NCT01820585</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia</brief_title>
  <official_title>Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia: a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre,
      multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS).
      Subjects were randomised in a 1:1:1:1 ratio to receive placebo, Eslicarbazepine acetate (ESL)
      400 mg once daily (QD), ESL 800 mg QD or ESL 1200 mg QD. The study was carried out as
      follows.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre,
      multinational, Phase II study in 528 subjects with pain due to FMS. Subjects were randomised
      in a 1:1:1:1 ratio to receive placebo, ESL 400 mg once daily (QD), ESL 800 mg QD or ESL 1200
      mg QD. The study was carried out as follows:

      Screening Visit (Visit [V] 1): After completing screening procedures at V1, eligible subjects
      began the 2 week Baseline Period.

      Baseline Period (2 weeks): Subjects discontinued taking prohibited medications on V1
      (beginning of washout period). Subjects were tapered off of discontinued medications. Washout
      was completed by Day -7 (7 days before V2). Subjects refrained from taking any pain
      medications and other prohibited medications (except rescue medication) throughout the study.
      During the Baseline Period, subjects used the subject diary to complete the diary pain
      assessment on a 0-10 numeric pain rating scale (NPRS) and to record information on rescue
      medication daily on awakening.

      Titration Period (1 week): Upon completing the Baseline Period, subjects returned to the
      study centre for V2 (Randomisation Visit, Day 1). At V2, subjects, who had completed at least
      4 subject diary pain assessments satisfactorily within the past 7 days, had an average pain
      score that was ≥4 and ≤9 and continued to meet all study entry criteria, were randomly
      assigned to 1 of the 4 treatment groups. During the 1-week Titration Period, subjects
      randomised to the ESL 400 mg QD and the ESL 800 mg QD treatment groups received ESL 400 mg
      QD; and subjects randomised to the ESL 1200 mg QD treatment group received ESL 600 mg QD;
      subjects assigned to placebo treatment received placebo QD.

      Maintenance Period (12 weeks): Starting at V3, subjects assigned to treatment with ESL
      received their full dosage regimens QD; subjects assigned to placebo treatment received
      placebo QD. During the Maintenance Period, subjects had visits every 4 weeks.

      Follow-up Period (2 weeks): Approximately 2 weeks after taking the last dose of study
      medication, subjects returned to the study centre for the Follow-up Visit and underwent the
      end-of-study evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline to Endpoint in Mean Pain</measure>
    <time_frame>Baseline and 13 Weeks</time_frame>
    <description>The primary efficacy variable was the absolute change from baseline to endpoint in mean pain. Pain intensity was assessed on an 11-point (0-10) Numeric pain rating scale (NPRS), where 0 = no pain and 10 = worst possible pain and was recorded in a subject's diary. The subject was instructed to complete the assessment daily on awakening.Primary analyses were conducted on the full analysis set (FAS) which consisted of all randomised subjects who received at least 1 dose of study medication and with at least 1 post-randomisation rating of 24-h-average pain. The primary efficacy variable was the absolute change from baseline to endpoint in mean pain recorded in a subject's diary upon awakening each morning. An ANCOVA on the FAS revealed no statistically significant differences between the 3 ESL groups and the placebo group after 13 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">528</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eslicarbazepine acetate (BIA 2-093) tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eslicarbazepine acetate (BIA 2-093) tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 1200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eslicarbazepine acetate (BIA 2-093) tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL 400 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>ESL 400 mg</arm_group_label>
    <other_name>Eslicarbazepine acetate (BIA 2-093)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL 800 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>ESL 800 mg</arm_group_label>
    <other_name>Eslicarbazepine acetate (BIA 2-093)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL 1200 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>ESL 1200 mg</arm_group_label>
    <other_name>Eslicarbazepine acetate (BIA 2-093)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was male or female, 18 years of age or older (according to Amendment #1 for
             Czech Republic [24 MARCH 2009]: 18 to 65 years of age).

          -  Subject was able and willing to provide written informed consent to participate in the
             study after having the opportunity to review the Subject Information Sheet and
             Informed Consent Form.

          -  Subject met the American College of Rheumatology (ACR) 1990 diagnostic criteria for
             FMS (widespread pain for at least 3 months and pain in at least 11 of 18 tender
             points) (according to Amendment #1 for Czech Republic [24 MARCH 2009]: and the
             subject's current FMS treatment was either inefficacious or had intolerable side
             effects).

          -  Subject was willing and able to understand and comply with all study requirements, in
             the judgment of the investigator.

          -  Subject had negative results on the urine test for drugs of abuse at V1 (Screening
             Visit), except for medications/drugs reported by the subject at the Screening Visit.

          -  Subject use of allowable non-pharmacological therapies was stable for at least 4 weeks
             prior to V1 (Screening Visit) and would be maintained at the stable regimen throughout
             the study.

          -  Female subject was surgically sterile (i.e. bilateral tubal ligation, bilateral
             oophorectomy or hysterectomy) or at least 2 years post-menopausal or, if of
             childbearing potential, she was sexually abstinent or agreed to use a medically
             acceptable non-hormonal method of contraception

          -  Addendum according to Amendment #1 for Czech Republic [24 MARCH 2009]: Hormonal
             contraceptives were not acceptable as a contraceptive method in this study. However,
             their intake was not forbidden throughout the study.

          -  Addendum according to Amendment #1 for Spain [19 JANUARY 2009] and for United Kingdom
             [24 MARCH 2009]: Male subject was sexually abstinent or agreed to use reliable
             contraceptive methods (i.e. double-barrier method: 1 male barrier [male condom] plus 1
             female barrier method [female condom, spermicide or intrauterine device]. This was
             mandatory even for sexually active men who had been sterilised.

          -  Subject had a negative urine test for drugs of abuse.

          -  The subject had completed at least 4 subject diary pain assessments satisfactorily
             within the past 7 days prior to V2 and the average pain score was ≥4 and ≤9.

        Exclusion Criteria:

          -  Subject had a known hypersensitivity to ESL or to other carboxamide derivatives (e.g.
             oxcarbazepine, carbamazepine) or to any of the excipients.

          -  Subject had a history of or current active malignancy except for the following: basal
             cell carcinoma which had been treated; and malignancies that were successfully treated
             and had no recurrence within 5 years before V1 (Screening Visit).

          -  Subject had a severe hepatic, renal, respiratory, hematologic or immunologic illness,
             unstable cardiovascular disease or any other medical or psychiatric condition that, in
             the judgment of the investigator, made the subject inappropriate for entry into this
             study.

          -  Subject had a second or third-degree atrioventricular blockade not corrected with a
             pacemaker or any other clinically significant abnormality in the 12-lead ECG as
             determined by the investigator.

          -  Subject had a history of illicit drug or alcohol abuse within 2 years before V1
             (Screening Visit).

          -  Subject had received an investigational drug (or a medical device) within 3 months of
             Screening or was currently participating in another study of an investigational drug
             (or a medical device).

          -  Subject was pregnant or nursing.

          -  Subject was an employee of the investigator or study centre, with direct involvement
             in the proposed study or other studies under the direction of that investigator or
             study centre or was a family member of the employees or the investigator.

          -  Subject had any of the following: an inflammatory muscle or rheumatologic disease
             other than FMS; multiple sclerosis; active infections; untreated endocrine disorders;
             uncontrolled hypo- or hyper-thyroidism of any type.

          -  Subjects whose pain was not due primarily to FMS.

          -  Subject underwent tender point injection within 30 days before V1 (Screening Visit)
             and/or subject was unwilling to refrain from tender point injection throughout the
             study.

          -  Subject had a white blood cell (WBC) count &lt;2.5 × 109/L, neutrophil count &lt;1.5 ×
             109/L, Na+ &lt;125 mmol/L or alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) ≥2 × the upper limit of normal at V1 (Screening Visit) or any other clinically
             relevant laboratory abnormality that, in the investigator's opinion, could compromise
             the subject's safety.

          -  Subject had abnormal values for antinuclear antibody (ANA &gt;1/160) or rheumatoid factor
             (RF &gt;15 IU/mL) at V1 (Screening Visit). After approval of the global amendment in
             respective countries, the limit for ANA was changed to ≥1/160.

          -  Subject had abnormal Westergren erythrocyte sedimentation rate (ESR) at V1 (Screening
             Visit) (ESR &gt;40 mm/h).

          -  Subject had creatinine clearance (CLCr) lower than 60 mL/min at Screening.

          -  Subject had a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥35 or a
             score of 4 to 6 on question 10 of the MADRS at V1 (Screening Visit).

          -  Subject used prohibited concomitant medications during the 2-week Baseline Period or
             used fluoxetine during the 30 days before V1 (Screening Visit).

          -  Subject used opiates every day for the 30 days before V1 (Screening Visit) for the
             control of pain related to FMS.

          -  Exclusion criterion at V2:

          -  Subject had a MADRS total score ≥35 or a score of 4 to 6 on question 10 of the MADRS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricio Soares-da-Silva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BIAL - Portela &amp; Cª, S.A.</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>June 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2013</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>Eslicarbazepine acetate (BIA 2-093)</keyword>
  <keyword>ESL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened in 84 centres in 16 European countries (Austria, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Ukraine and United Kingdom).
Study initiation date: 21 Apr 2009 Study completion date: 03 Sep 2010;</recruitment_details>
      <pre_assignment_details>After completing procedures at V1, subjects returned to the study centre for V2. At V2, subjects, who had completed at least 4 subject diary pain assessments satisfactorily within the past 7 days, had an average pain score that was ≥4 and ≤9 and continued to meet all study entry criteria, were randomly assigned to 1 of the 4 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablets matching the 400-mg and 600-mg tablets were administered Once daily (QD) by oral route.</description>
        </group>
        <group group_id="P2">
          <title>ESL 400 mg</title>
          <description>Eslicarbazepine acetate (ESL) 400 mg : ESL was supplied in 400-mg tablets and was administered QD by oral route.</description>
        </group>
        <group group_id="P3">
          <title>ESL 800 mg</title>
          <description>ESL 800 mg : ESL was supplied in 400-mg tablets and was administered QD by oral route</description>
        </group>
        <group group_id="P4">
          <title>ESL 1200 mg</title>
          <description>ESL was supplied in 400-mg and 600-mg tablets and was administered QD by oral route.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Titration Period</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>at sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Tablets
Placebo : Tablets</description>
        </group>
        <group group_id="B2">
          <title>ESL 400 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 400 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
        <group group_id="B3">
          <title>ESL 800 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 800 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
        <group group_id="B4">
          <title>ESL 1200 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 1200 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="132"/>
            <count group_id="B5" value="528"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline to Endpoint in Mean Pain</title>
        <description>The primary efficacy variable was the absolute change from baseline to endpoint in mean pain. Pain intensity was assessed on an 11-point (0-10) Numeric pain rating scale (NPRS), where 0 = no pain and 10 = worst possible pain and was recorded in a subject’s diary. The subject was instructed to complete the assessment daily on awakening.Primary analyses were conducted on the full analysis set (FAS) which consisted of all randomised subjects who received at least 1 dose of study medication and with at least 1 post-randomisation rating of 24-h-average pain. The primary efficacy variable was the absolute change from baseline to endpoint in mean pain recorded in a subject’s diary upon awakening each morning. An ANCOVA on the FAS revealed no statistically significant differences between the 3 ESL groups and the placebo group after 13 weeks of treatment.</description>
        <time_frame>Baseline and 13 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tablets
Placebo : Tablets</description>
          </group>
          <group group_id="O2">
            <title>ESL 400 mg</title>
            <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 400 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
          </group>
          <group group_id="O3">
            <title>ESL 800 mg</title>
            <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 800 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
          </group>
          <group group_id="O4">
            <title>ESL 1200 mg</title>
            <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 1200 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline to Endpoint in Mean Pain</title>
          <description>The primary efficacy variable was the absolute change from baseline to endpoint in mean pain. Pain intensity was assessed on an 11-point (0-10) Numeric pain rating scale (NPRS), where 0 = no pain and 10 = worst possible pain and was recorded in a subject’s diary. The subject was instructed to complete the assessment daily on awakening.Primary analyses were conducted on the full analysis set (FAS) which consisted of all randomised subjects who received at least 1 dose of study medication and with at least 1 post-randomisation rating of 24-h-average pain. The primary efficacy variable was the absolute change from baseline to endpoint in mean pain recorded in a subject’s diary upon awakening each morning. An ANCOVA on the FAS revealed no statistically significant differences between the 3 ESL groups and the placebo group after 13 weeks of treatment.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1735"/>
                    <measurement group_id="O2" value="-0.8" spread="0.1731"/>
                    <measurement group_id="O3" value="-1.2" spread="0.1704"/>
                    <measurement group_id="O4" value="-0.8" spread="0.1734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were evaluated throughout the study that consisted of a 2-week Baseline Period, a 1-week Titration Period (active treatment or placebo) and a 12- week Maintenance Period (active treatment or placebo).</time_frame>
      <desc>Safety was evaluated based on adverse events (AEs)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Tablets
Placebo : Tablets</description>
        </group>
        <group group_id="E2">
          <title>ESL 400 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 400 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
        <group group_id="E3">
          <title>ESL 800 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 800 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
        <group group_id="E4">
          <title>ESL 1200 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) tablets
ESL 1200 mg : Eslicarbazepine acetate (BIA 2-093) tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="135"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyl transferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="130"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="135"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>Bial - Portela &amp; Cª, S.A.</organization>
      <phone>+ 351 22 986 61 00</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

